^
    Back
    Association details:
    Biomarker:PTEN mutation
    Cancer:Triple Negative Breast Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

    Excerpt:
    ...Changes in Gene Expression in Tumor Tissue as Assessed by Ribonucleic Acid-sequencing (RNA-seq)`Assignment of a Triple Negative Subtype in Tumor Tissue as Assessed by Ribonucleic Acid-sequencing (RNA-seq)`Define Mutations Present in the Tumors as Assessed by Ribonucleic Acid-sequencing (RNA-seq)`Somatic Single Nucleotide Polymorphisms (SNPs) and Structural Variants in Tumor Tissue and Blood as Assessed by Whole Exome Sequencing (WES)`Status of p53, BRCA1/2, PIK3CA, PTEN, INPP4B and Other Mutations...
    Trial ID:
    NCT03206203
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Res
    Title:

    Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)

    Excerpt:
    ...26% of pts received monotherapy [pembrolizumab (n=7, NCT02447003); atezolizumab (n=6; NCT01375842)]...PTEN alterations were present in 30% of pts....Pts with tumors harboring PTEN alterations had lower ORR (7% vs 57%; P<0.001), shorter median PFS (2.3 vs 6.3 months; P=0.027), and shorter median OS (8.1 vs 20.1 months; P=0.012) compared to pts without PTEN alterations.
    DOI:
    10.1158/1538-7445.SABCS18-P5-12-02
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Res
    Title:

    Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)

    Excerpt:
    74% received combination with CT [pembrolizumab plus eribulin (n=31; NCT02513472); atezolizumab plus nab-paclitaxel (n=6; NCT01633970)]. PTEN alterations were present in 30% of pts....Pts with tumors harboring PTEN alterations had lower ORR (7% vs 57%; P<0.001), shorter median PFS (2.3 vs 6.3 months; P=0.027), and shorter median OS (8.1 vs 20.1 months; P=0.012) compared to pts without PTEN alterations.
    Secondary therapy:
    albumin-bound paclitaxel
    DOI:
    10.1158/1538-7445.SABCS18-P5-12-02